Surmodics receives IDE approval to initiate pivotal trial of the SurVeilTM DCB
Surmodics announced it has received an investigational device exemption from the FDA to initiate a pivotal clinical trial of the SurVeil™ drug-coated balloon. The randomized trial will evaluate the SurVeil DCB for treatment for PAD in the upper leg compared to the Medtronic IN.PACT® Admiral® DCB. July 26, 2017